These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16838842)

  • 1. Inhibition of VEGF mRNA by 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) antisense oligonucleotides and their influence on off-target gene expressions.
    Morita K; Yamate K; Kurakata S; Abe K; Watanabe K; Koizumi M; Imanishi T
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(4-6):503-21. PubMed ID: 16838842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) for effective antisense formation.
    Morita K; Yamate K; Kurakata S; Watanabe K; Imanishi T; Koizumi M
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1619-21. PubMed ID: 14565480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of VEGF mRNA expression by 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) antisense oligonucleotides and investigation of non-target gene expression.
    Morita K; Yamate K; Kurakata S; Abe K; Imanishi T; Koizumi M
    Nucleic Acids Res Suppl; 2002; (2):99-100. PubMed ID: 12903124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the RNase H cleavage kinetics and blood serum stability of the north-conformationally constrained and 2'-alkoxy modified oligonucleotides.
    Honcharenko D; Barman J; Varghese OP; Chattopadhyaya J
    Biochemistry; 2007 May; 46(19):5635-46. PubMed ID: 17411072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of ENA gapmers as fine-tuning antisense oligonucleotides with sequence-specific inhibitory activity on mouse PADI4 mRNA expression.
    Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
    Nucleic Acids Symp Ser (Oxf); 2006; (50):319-20. PubMed ID: 17150946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fine-tuning of ENA gapmers as antisense oligonucleotides for sequence-specific inhibition.
    Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
    Oligonucleotides; 2007; 17(3):291-301. PubMed ID: 17854269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2',4'-carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties.
    Zhou C; Liu Y; Andaloussi M; Badgujar N; Plashkevych O; Chattopadhyaya J
    J Org Chem; 2009 Jan; 74(1):118-34. PubMed ID: 19055352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five- and six-membered conformationally locked 2',4'-carbocyclic ribo-thymidines: synthesis, structure, and biochemical studies.
    Srivastava P; Barman J; Pathmasiri W; Plashkevych O; Wenska M; Chattopadhyaya J
    J Am Chem Soc; 2007 Jul; 129(26):8362-79. PubMed ID: 17552524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA in comparison of that of 2'-MOE-modified oligonucleotides.
    Koizumi M; Takagi-Sato M; Okuyama R; Araki K; Sun W; Nakai D
    Nucleic Acids Symp Ser (Oxf); 2007; (51):111-2. PubMed ID: 18029611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformationally constrained 2'-N,4'-C-ethylene-bridged thymidine (aza-ENA-T): synthesis, structure, physical, and biochemical studies of aza-ENA-T-modified oligonucleotides.
    Varghese OP; Barman J; Pathmasiri W; Plashkevych O; Honcharenko D; Chattopadhyaya J
    J Am Chem Soc; 2006 Nov; 128(47):15173-87. PubMed ID: 17117869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells.
    Aukunuru JV; Ayalasomayajula SP; Kompella UB
    J Pharm Pharmacol; 2003 Sep; 55(9):1199-206. PubMed ID: 14604462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.
    Saleh M; Stacker SA; Wilks AF
    Cancer Res; 1996 Jan; 56(2):393-401. PubMed ID: 8542597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibitory effects of antisense oligonucleotides on VEGF gene expression by human hepatocellular carcinoma cells].
    Gong BD; Luo W; Du FT; Ye RM; Liu JM; Yu CG; Zou YQ; Zhang JX
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jan; 12(1):35-7. PubMed ID: 14761281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of the inhibitory activity of oatp antisense oligonucleotides by incorporation of 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) without a loss of subtype selectivity.
    Takagi M; Morita K; Nakai D; Nakagomi R; Tokui T; Koizumi M
    Biochemistry; 2004 Apr; 43(15):4501-10. PubMed ID: 15078096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct comparison of in vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA with that of 2'-O-(2-methoxy)ethyl-modified oligonucleotides.
    Koizumi M; Takagi-Sato M; Okuyama R; Araki K; Sun W; Nakai D; Tsutsumi S; Kawai K
    Oligonucleotides; 2006; 16(3):253-62. PubMed ID: 16978088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel human prostate-specific gene-1 (HPG-1): molecular cloning, sequencing, and its potential involvement in prostate carcinogenesis.
    Herness EA; Naz RK
    Cancer Res; 2003 Jan; 63(2):329-36. PubMed ID: 12543784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers.
    Kitamura S; Kondo S; Shinomura Y; Kanayama S; Miyazaki Y; Kiyohara T; Hiraoka S; Matsuzawa Y
    Br J Cancer; 2000 Sep; 83(5):668-73. PubMed ID: 10944610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of VEGF mRNA antisense oligodeoxynucleotides by RNA structure software and their effects on HL60 and K562 cells.
    Fei J; Zhang Y
    Cell Biol Int; 2005 Sep; 29(9):737-41. PubMed ID: 15985377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues.
    Bacic M; Edwards NA; Merrill MJ
    Growth Factors; 1995; 12(1):11-5. PubMed ID: 8527159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo.
    Riedel F; Götte K; Li M; Hörmann K; Grandis JR
    Int J Oncol; 2003 Sep; 23(3):577-83. PubMed ID: 12888890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.